Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes after robotic thymectomy in nonthymomatous versus thymomatous patients with acetylcholine-receptor-antibody-associated myasthenia gravis.
Marcuse F, Hoeijmakers JGJ, Hochstenbag M, Hamid MA, Keijzers M, Mané-Damas M, Martinez-Martinez P, Verschuuren J, Kuks J, Beekman R, van der Kooi AJ, van Doorn P, van Es M, Maessen JJG, De Baets MHV. Marcuse F, et al. Among authors: hochstenbag m. Neuromuscul Disord. 2023 May;33(5):417-424. doi: 10.1016/j.nmd.2023.03.005. Epub 2023 Mar 16. Neuromuscul Disord. 2023. PMID: 37037051 Free article.
Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study.
De Ruysscher D, Wanders S, Minken A, Lumens A, Schiffelers J, Stultiens C, Halders S, Boersma L, Baardwijk Av, Verschueren T, Hochstenbag M, Snoep G, Wouters B, Nijsten S, Bentzen SM, Kroonenburgh Mv, Ollers M, Lambin P. De Ruysscher D, et al. Among authors: hochstenbag m. Radiother Oncol. 2005 Oct;77(1):5-10. doi: 10.1016/j.radonc.2005.06.014. Epub 2005 Jul 12. Radiother Oncol. 2005. PMID: 16019093 Clinical Trial.
Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer.
De Ruysscher D, Dehing C, Yu S, Wanders R, Ollers M, Dingemans AM, Bootsma G, Hochstenbag M, Geraedts W, Pitz C, Simons J, Boersma L, Borger J, Dekker A, Lambin P. De Ruysscher D, et al. Among authors: hochstenbag m. Radiother Oncol. 2009 Jun;91(3):353-9. doi: 10.1016/j.radonc.2008.10.006. Epub 2008 Nov 13. Radiother Oncol. 2009. PMID: 19012981
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM. Groen HJ, et al. Among authors: hochstenbag mm. J Clin Oncol. 2011 Nov 10;29(32):4320-6. doi: 10.1200/JCO.2011.35.5214. Epub 2011 Oct 11. J Clin Oncol. 2011. PMID: 21990410 Clinical Trial.
Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study.
van Loon J, Grutters J, Wanders R, Boersma L, Oellers M, Dingemans AM, Bootsma G, Geraedts W, Pitz C, Simons J, Fatah SA, Snoep G, Hochstenbag M, Lambin P, De Ruysscher D. van Loon J, et al. Among authors: hochstenbag m. Eur J Cancer. 2009 Mar;45(4):588-95. doi: 10.1016/j.ejca.2008.10.017. Epub 2008 Dec 4. Eur J Cancer. 2009. PMID: 19046631
Can we optimize chemo-radiation and surgery in locally advanced stage III non-small cell lung cancer based on evidence from randomized clinical trials? A hypothesis-generating study.
De Ruysscher D, Dehing C, Bentzen SM, Houben R, Dekker A, Wanders R, Borger J, Hochstenbag M, Boersma L, Geskes G, Dingemans AM, Bootsma G, Lammering G, Lambin P. De Ruysscher D, et al. Among authors: hochstenbag m. Radiother Oncol. 2009 Dec;93(3):389-95. doi: 10.1016/j.radonc.2009.06.004. Epub 2009 Jul 1. Radiother Oncol. 2009. PMID: 19576645 Review.
Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study.
van Loon J, De Ruysscher D, Wanders R, Boersma L, Simons J, Oellers M, Dingemans AM, Hochstenbag M, Bootsma G, Geraedts W, Pitz C, Teule J, Rhami A, Thimister W, Snoep G, Dehing-Oberije C, Lambin P. van Loon J, et al. Among authors: hochstenbag m. Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):329-36. doi: 10.1016/j.ijrobp.2009.04.075. Epub 2009 Sep 24. Int J Radiat Oncol Biol Phys. 2010. PMID: 19782478
Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer.
De Ruysscher D, Pijls-Johannesma M, Bentzen SM, Minken A, Wanders R, Lutgens L, Hochstenbag M, Boersma L, Wouters B, Lammering G, Vansteenkiste J, Lambin P. De Ruysscher D, et al. Among authors: hochstenbag m. J Clin Oncol. 2006 Mar 1;24(7):1057-63. doi: 10.1200/JCO.2005.02.9793. J Clin Oncol. 2006. PMID: 16505424
51 results